ABSTRACT
INTRODUCTION
Multiple myeloma (MM) is a neoplastic proliferation of plasma cells that usually is treated with various chemotherapy regimens, including immunomodulatory drugs. 1 Lenalidomide (Revlimid, Celgene Corporation, Summit, NJ), an immunomodulatory agent approved by the US Food and Drug Administration (FDA) in 2006 for treatment of MM, 2, 3 is associated with the development of secondary cancers. 4 The FDA issued a statement in 2012 about the increased risk of secondary primary malignancies (SPMs) in patients with newly diagnosed MM who received lenalidomide. 5 However, the FDA statement did not include glioblastoma multiforme (GBM), a Grade 4 astrocytoma with a poor prognosis, or other high-grade astrocytomas. Here we present a rare case of a patient with MM who was treated with lenalidomide and in whom GBM developed as an SPM. We also present a literature review of GBM and highgrade astrocytomas occurring as the SPM in MM.
CASE PRESENTATION

Presenting Concerns
A 72-year-old man presented to our hospital with 6-weeks of confusion, headache, nausea and vomiting, and recurrent falls. His medical history was remarkable for λ-light-chain MM diagnosed 4 years earlier (immunoglobulin G predominant with 60% plasma cells on bone marrow; Durie-Salmon Stage II, Group A; International Staging System Stage I). After experiencing symptoms related to MM, our patient underwent 4 cycles of bortezomib (Velcade, Takeda Pharmaceuticals, Cambridge, MA), lenalidomide (Revlimid), and low-dose dexamethasone, followed by autologous stem cell transplantation, and then lenalidomide maintenance therapy for 2 years. He had been in complete remission for 1 year before presentation. Other medical conditions included hyperlipidemia, hypertension, and insulin-dependent diabetes mellitus. He denied use of tobacco, alcohol, or illicit drugs. His family history was notable for diabetes mellitus and hypertension.
On presentation, his vital signs were normal. The patient was alert but not oriented. He had expressive aphasia, unsteady gait, and masked facies.
Biochemical and hematologic investigations yielded normal results apart from the following values: Glucose 108 mg/dL (reference range = 70-99 mg/dL), total protein 5.4 mg/dL (6.4-8.3 mg/dL), albumin 3.0 mg/dL (3.5-5.2 mg/dL), mean corpuscular volume 104.6 fL (80-100 fL), platelets 83 × 10 9 /L (150-450 × 10 9 /L), and vitamin B 12 above 1500 pg/mL (211-911 pg/mL).
Magnetic resonance imaging of the brain with and without contrast enhancement revealed a heterogenous mass (4.9 × 4.5 × 6 cm 3 ) in the left temporal lobe extending into the uncus and 
Therapeutic Intervention and Treatment
Dexamethasone and levetiracetam were given to decrease the vasogenic edema and for seizure prophylaxis, respectively. We sought the opinion of a neurosurgeon, who advised forgoing complete tumor resection because the location in the dominant temporal lobe and the presence of aphasia made the procedure too risky. Repeated brain imaging after biopsy showed development of a communicating hydrocephalus, for which a ventriculostomy shunt was placed. Within 48 hours of shunt placement, the patient's mental status improved and his symptoms of headache and nausea/ vomiting resolved.
During the next 4 weeks, the patient received 10 sessions of palliative wholebrain radiation therapy at 30 Gy to 40 Gy.
Follow-up and Outcomes
Our patient's clinical status deteriorated, and his power of attorney opted for hospice care. He died four months later because of complications secondary to hospital-associated pneumonia. Table 1 shows a timeline of the case.
DISCUSSION
Multiple myeloma is a neoplastic proliferation of plasma cells producing a monoclonal gammopathy with related organ or tissue impairment. 1 Newly diagnosed patients undergo induction therapy with corticosteroids plus proteasome inhibitors bortezomib or carfilzomib, thalidomide or immunomodulatory drugs lenalidomide or pomalidomide, and/or alkylating agents (eg, cyclophosphamide or melphalan), followed by autologous stem cell transplant if eligible and maintenance with thalidomide or lenalidomide and/or corticosteroids until disease progression or intolerance to treatment develops. 1 Lenalidomide, a derivative of thalidomide, is an immunomodulatory drug approved by the FDA for treatment of MM in 2006. 2, 3 In 2012, Yang et al 4 compared three Phase 3 trials examining maintenance therapy with lenalidomide vs placebo and found a nearly three-fold increase in invasive malignancies, especially hematologic malignancies, in patients with MM receiving lenalidomide. That same year, the FDA issued a warning statement about hematologic SPMs, including acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma, after MM maintenance therapy with lenalidomide. 5 One uncommon nonhematologic SPM is GBM, a Grade 4 astrocytoma. It is a solid tumor involving glial cells of the brain and is the most common primary and malignant brain tumor, in addition to the most aggressive. 6 High-grade astrocytomas are extremely rare in the setting of MM and have been reported previously in 6 studies, all of which are summarized in Table 2 . [7] [8] [9] [10] [11] [12] Our patient is the 7th reported case. The exact etiology in this setting is unclear, and researchers have postulated it to be multifactorial, involving the treatment, MM itself, patient characteristics, and factors in the environment and human behavior. 13 To our knowledge, no other cases of GBM arising after MM treatment with lenalidomide have been reported. Our case report reiterates the risk of developing SPMs in the setting of MM. Our case also highlights the potential association with lenalidomide and increased risk of tumors such as high-grade astrocytomas, including GBM, because it is not uncommon for patients with one malignancy to have another develop. v
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